Health Canada
Symbol of the Government of Canada
Skip to content | Skip to institutional links

Common menu bar links

Home > First Nations, Inuit & Aboriginal Health > Reports & Publications > Non-Insured Health Benefits > Updates to the Drug Benefit List - Summer 2009

Institutional links

First Nations, Inuit and Aboriginal Health

Updates to the Drug Benefit List - Summer 2009

The Non-Insured Health Benefits (NIHB) Program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada. Visit our Web Site at: www.healthcanada.gc.ca/nihb/

Benefit Definitions

Open Benefits
Open benefits are the drugs listed in the NIHB Drug Benefit List (DBL) which do not have established criteria or prior approval requirements.
Limited Use Benefits
Limited use drugs are those that have been found to be effective in specific circumstances, or which have quantity and frequency limitations. For drugs in this category, specific criteria must be met to be eligible for coverage.
Not Added To Formulary
Drugs not added to formulary are those which are not listed in the NIHB DBL after review by the national Common Drug Review (CDR) process and/or the Federal Pharmacy and Therapeutics Committee (FPT). These drugs will not be added to the NIHB drug list because published evidence does not support the clinical value or cost of the drug relative to existing therapies. Coverage may be considered in special circumstances upon receipt of a completed "Exception Drugs Request Form". These requests are reviewed on a case by case basis.
Exclusions
Certain drug therapies for particular conditions fall outside of the NIHB mandate and will not be provided as benefits under the NIHB Program (e.g., cosmetic and anti-obesity drugs). As well, certain drugs will be excluded from the NIHB Program as recommended by the CDR and the FPT because published evidence does not support the clinical value, safety or cost of the drug relative to existing therapies, or there is insufficient clinical evidence to support coverage.

Note: The appeal process and the emergency supply policy will not apply to excluded drugs.

DIN (Drug Identification Number)
MFR (Three letter identification code assigned to manufacturer name)
ST (Short-term Dispensing Policy Drug)

Additions to the Drug Benefit List

Open Benefits

Single-Source Drug Products
DIN MFR Brand Name Effective Date
00964905 TRU AEROCHAMBER AC BOYZ 01/08/2009
00964891 TRU AEROCHAMBER AC GIRLZ 01/08/2009
02279460 SAC APIDRA 100UNIT/ML INJECTION 21/07/2009
02294346 SAC APIDRA SOLOSTAR PREFILLED PEN 21/07/2009
00262609 TCH CITRO MAG 15GM/300ML INJECTION 12/05/2009
80003010 EUR STEURO D 800IU CAPSULE 03/09/2009
99100159 PFI FRAGMIN 7500U/0.3ML INJECTION 30/06/2009
02318709 BOV STMICARDIS PLUS 25MG/80MG TABLET 10/08/2009
02285576 LAP NORLEVO 0.75MG TABLET 10/08/2009
09991126 CSU OMNIFLEX DIAPHRAGM 75 01/05/2009
02305941 NOV STSTALEVO 100MG/25MG/200MG TABLET 26/06/2009
02305968 NOV STSTALEVO 150MG/37.5MG/200MG TABLET 26/06/2009
02305933 NOV STSTALEVO 50MG/12.5MG/200MG TABLET 26/06/2009
00122645 JAM STVITAMIN B6 25MG TABLET 05/07/2009
00122858 JAM STVITAMIN E 400IU NAT SOURCE CAPSULE 07/09/2009
02321157 BAY YAZ TABLET 10/08/2009
Multi-Source Drug Products
DIN MFR Brand Name Effective Date
01958836 TRI ACETAMINOPHENE 160MG/5ML SYRUP 22/05/2009
02273381 APX STAPO-AMLODIPINE 10MG TABLET 19/08/2009
02273373 APX STAPO-AMLODIPINE 5MG TABLET 19/08/2009
02296063 APX APO-BICALUTAMIDE 50MG TABLET 03/09/2009
02327856 APX STAPO-HYDRO 12.5MG TABLET 19/08/2009
02325381 APX STAPO-RAMIPRIL 15MG CAPSULE 10/08/2009
02324199 NOP STCALCIUM CARB/ETIDRONATE DISODI 25/05/2009
00297493 CBT STCO AMLODIPINE 10MG TABLET 19/08/2009
02297485 CBT STCO AMLODIPINE 5MG TABLET 19/08/2009
02281279 CBT CO FLUCONAZOLE 100MG TABLET 26/05/2009
02323419 CBT CO FLUCONAZOLE 150MG CAPSULE 04/09/2009
02297302 CBT STCO PRAMIPEXOLE 0.25MG TABLET 25/05/2009
02297310 CBT STCO PRAMIPEXOLE 0.5MG TABLET 25/05/2009
02297337 CBT STCO PRAMIPEXOLE 1.5MG TABLET 25/05/2009
02297329 CBT STCO PRAMIPEXOLE 1MG TABLET 25/05/2009
02296349 CBT CO-ONDANSETRON 4MG TABLET 19/08/2009
02296357 CBT CO-ONDANSETRON 8MG TABLET 19/08/2009
02316846 CBT STCO-ROPINIROLE 0.25MG TABLET 03/09/2009
02316854 CBT STCO-ROPINIROLE 1MG TABLET 03/09/2009
02316862 CBT STCO-ROPINIROLE 2MG TABLET 03/09/2009
02316870 CBT STCO-ROPINIROLE 5MG TABLET 03/09/2009
02303825 EUR STEURO-DOCUSATE 100MG CAPSULE 03/09/2009
02285673 EUR STEURO-FOLIC 5MG TABLET 24/07/2009
02272121 GEN STGEN-AMLODIPINE 10MG TABLET 19/08/2009
02272113 GEN STGEN-AMLODIPINE 5MG TABLET 19/08/2009
02329425 GEN STGEN-OMEPRAZOLE 10MG CAPSULE LA 11/09/2009
02310880 APX IBUPROFEN ES 400MG LIQUID CAPSULE 30/06/2009
02317338 JAP JAMP IBUPROFEN 400MG CAPLETS 03/06/2009
02298503 JAP JAMP-DIPHENHYDRAMINE 12.5MG/5M 06/04/2009
80009357 JAP JAMP-MAGNESIUM GLUCE 100MG/ML 03/06/2009
80009539 JAP JAMP-MAGNESIUM GLUCONATE 500MG 04/09/2009
80008471 JAP STJAMP-MULTIVITAMIN A/D/ C DROPS 03/06/2009
80009183 JAP STJAMP-SENNOSIDES 12MG TABLET 03/06/2009
80009182 JAP STJAMP-SENNOSIDES 8.6MG TABLET 06/04/2009
80009633 JAP STJAMP-VITAMIN B1 50MG TABLET 07/07/2009
02317427 MIN MINT-CIPROFLOXACIN 250MG TABLET 19/08/2009
02317435 MIN MINT-CIPROFLOXACIN 500MG TABLET 19/08/2009
02317443 MIN MINT-CIPROFLOXACIN 750MG TABLE 19/08/2009
02317451 MIN STMINT-PRAVASTATIN 10MG TABLET /08/2009
02317478 MIN STMINT-PRAVASTATIN 20MG TABLET 19/08/2009
02317486 MIN STMINT-PRAVASTATIN 40MG TABLET 19/08/2009
02297868 MYL MYLAN-ONDANSETRON 4MG TABLET 01/07/2009
02250500 NOP STNOVO-AMLODIPINE 10MG TABLET 19/08/2009
02250497 NOP STNOVO-AMLODIPINE 5MG TABLET 19/08/2009
80000435 NOP NOVO-FERROGLUC 300MG TABLET 04/09/2009
02316544 PDL STPDL-GLYBURIDE 5MG TABLE 01/06/2009
02326787 PMI STPHL-AMLODIPINE 10MG TABLET 02/09/2009
02326779 PMI STPHL-AMLODIPINE 5MG TABLET 02/09/2009
02246314 PMI PHL-GABAPENTIN 100MG TABLET 02/09/2009
02246315 PMI PHL-GABAPENTIN 300MG TABLET 02/09/2009
02246316 PMI PHL-GABAPENTIN 400MG TABLET 02/09/2009
02284073 PMS STPMS-AMLODIPINE 10MG TABLET 19/08/2009
02284065 PMS STPMS-AMLODIPINE 5MG TABLET 19/08/2009
00757705 PMS PMS-DIMENHYDRINATE SYRUP 21/08/2009
02326590 PMS STPMS-ROPINIROLE 0.25MG TABLET 21/08/2009
02326612 PMS STPMS-ROPINIROLE 1MG TABLET 21/08/2009
02326620 PMS STPMS-ROPINIROLE 2MG TABLET 21/08/2009
02326639 PMS STPMS-ROPINIROLE 5MG TABLET 21/08/2009
02294273 PMS PMS-TERBINAFINE 250MG TABLET 19/08/2009
02232658 PDL PROCET-30 TABLET 01/07/2009
02321866 RBY TRAN-AMLODIPINE 10MG TABLET 19/08/2009
02321858 RBY STRAN-AMLODIPINE 5MG TABLET 19/08/2009
02314037 RBY STRAN-SIMVASTATIN 0.25MG TABLET 21/08/2009
02329158 RBY STRAN-SIMVASTATIN 10MG TABLET 31/08/2009
02329166 RBY STRAN-SIMVASTATIN 20MG TABLET 31/08/2009
02329174 RBY STRAN-SIMVASTATIN 40MG TABLET 31/08/2009
02329131 RBY STRAN-SIMVASTATIN 50MG TABLET 31/08/2009
02329182 RBY STRAN-SIMVASTATIN 80MG TABLET 31/08/2009
02259613 RAT STRATIO-AMLODIPINE 10MG TABLET 19/08/2009
02259605 RAT TRATIO-AMLODIPINE 5MG TABLET 19/08/2009
02311194 RAT STRATIO-RAMIPRIL 15MG CAP 19/08/2009
02284391 SDZ STSANDOZ-AMLODIPINE 10MG TABLET 19/08/2009
00284383 SDZ STSANDOZ-AMLODIPINE 5MG TABLET 19/08/2009
02320312 SDZ SANDOZ-METHYLPHENIDATE SR 20MG TABLET 02/06/2009
02323508 SIG STSIG-ENALAPRIL 16MG TABLET 07/07/2009
02323478 SIG STSIG-ENALAPRIL 2MG TABLET 07/07/2009
02323486 SIG STSIG-ENALAPRIL 4MG TABLET 07/07/2009
02323494 SIG STSIG-ENALAPRIL 8MG TABLET 07/07/2009
80008590 BMI STVITAMIN D 400IU CAPSULE 28/05/2009
80008446 BMI STVITAMIN D 800 IU CAPSULE 28/05/2009
02321750 ZYM STZYM-ASA 80MG TABLET 30/06/2009
02321769 ZYM STZYM-ASA EC 80MG TABLET 30/06/2009

Top of Page

New Limited Use Benefits

Single-Source Drug Products
DIN MFR Brand Name Effective Date
02293269 MYL STCAMPRAL 333MG DR TABLET 01/09/2009

Limited use benefit (prior approval required).

For patients who have been abstinent from alcohol for at least four days and where available, are currently enrolled in an alcohol addiction treatment program.

DIN MFR Brand Name Effective Date
02275090 BOV WELLBUTRIN XL 150MG TABLET 01/09/2009
02275104 BOV WELLBUTRIN XL 300MG TABLET 01/09/2009

Limited use benefit (prior approval required).

For patients who are unresponsive to or intolerant of one other listed antidepressant.

Note: This product will not be approved for coverage for smoking cessation.

DIN MFR Brand Name Effective Date
02273225 NOV STENABLEX 15MG SR TABLET 01/09/2009
02273217 NOV STENABLEX 7.5MG SR TABLET 01/09/2009

Limited use benefit (prior approval required).

For the symptomatic relief of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence or any combination of these in patients who have failed on or are intolerant of therapy with oxybutynin.

DIN MFR Brand Name Effective Date
02301482 LIL CYMBALTA 30MG DR CAPSULE 26/06/2009
02301490 LIL CYMBALTA 60MG DR CAPSULE 26/06/2009

Limited use benefit (prior approval required).

For the treatment of neuropathic pain in patients with diabetes who have:

  1. failed an adequate trial with TWO alternative agents (such as a tricyclic; antidepressant or anticonvulsant) due to intolerance or lack of response OR
  2. a contraindication to alternative agents.

The dose of duloxetine will be limited to a maximum of 60 mg daily. Note that NIHB has adopted a Common Drug Review CEDAC recommendation that Cymbalta NOT be added to public drug plan formularies for the treatment of major depressive disorder.

DIN MFR Brand Name Effective Date
02306778 JNO INTELENCE 100MG TABLET 29/06/2009

Limited use benefit (prior approval required).

For use in combination with other antiretroviral agents for treatment-experienced patients with HIV-1 infection who have failed prior antiretroviral therapy; AND who have HIV-1 strains resistant to multiple antiretroviral agents, including NNRTIs.

DIN MFR Brand Name Effective Date
02299844 PFI CELSENTRI 150MG TABLET 13/08/2009
02299852 PFI CELSENTRI 300MG TABLET 13/08/2009

Limited use benefit (prior approval required).

For the treatment of HIV-1 infection, given in combination with other antiretroviral agents, in patients who have:

  1. CCR5 tropic viruses AND
  2. documented resistance to at least one agent from each of the three major classes of antiretroviral agents (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors).

DIN MFR Brand Name Effective Date
02323192 PFR OXYCONTIN 15MG CR TABLET 10/08/2009
02323206 PFR OXYCONTIN 30MG CR TABLET 10/08/2009
02323214 PFR OXYCONTIN 60MG CR TABLET 10/08/2009

Limited use benefit (prior approval required) for controlled release tablets only. Regular release dosage forms are full benefits and do not require prior approval.

For treatment of moderate to severe chronic pain when other opioids such as morphine have been ineffective in controlling pain or in patients experiencing intolerable side effects.

DIN MFR Brand Name Effective Date
02267233 NCC STTECTA 40MG TABLET 18/08/2009

Limited use benefit (prior approval required).

As part of multi-drug therapy (maximum 7-14 day coverage) for eradication of Helicobacter pylori in individuals with peptic ulcer disease (diagnosed by urea breath test, serology or endoscopically).

Coverage will also be provided if the following prerequisites are met:

  • patient has tried at least 30 days of Omeprazole (Losec®), AND
  • patient has tried at least 30 days of Rabeprazole sodium (Pariet®).

Total trial of 60 days will be confirmed against medication history.

PLUS

  • for treatment of confirmed gastric and duodenal ulcers. Or
  • for mild to moderate gastroesophageal reflux disease (GERD) in patients who have failed on or not tolerated and 4-week trial of histamine-2 receptor antagonists. Or
  • for severe gastroesophageal reflux disease (GERD) and complications as first-line therapy for a maximum period of 3 months. Patients should be reassessed endoscopically or with step-down therapy using a histamine-2 receptor antagonist. Or
  • for treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers where the NSAID must be continued. Or
  • for prevention of NSAID-induced ulcers in patients who have a history of ulcer complications, are over the age of 65 years, have comorbid disease such as cardiovascular disease or coagulopathies or are on concomitant medications which increase risk of ulcers or bleeding. Or
  • Zollinger-Ellison Syndrome*. Or
  • Barrett's Esophagus*. Or
  • esophagitis associated with connective tissue disease. Or
  • other exceptional circumstances, evaluated on an individual basis.

*Diagnosis must be confirmed by a specialist qualified to diagnose and treat condition.

DIN MFR Brand Name Effective Date
02298597 PFI ZELDOX 20MG CAPSULE 29/06/2009
02298600 PFI ZELDOX 40MG CAPSULE 29/06/2009
02298619 PFI ZELDOX 60MG CAPSULE 29/06/2009
02298627 PFI ZELDOX 80MG CAPSULE 29/06/2009

Limited use benefit (prior approval required).

For the treatment of schizophrenia and schizoaffective disorders in patients who have:

  1. intolerance or lack of response to an adequate trial of another antipsychotic agent OR
  2. a contraindication to another antipsychotic agent.
Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02299712 PMI STPHL-ALENDRONATE-FC 70MG TABLET 14/09/2009

Limited use benefit (prior approval required).

For treatment of:

  1. osteoporosis in patients who have documented hip, vertebral or other fractures,
  2. osteoporosis in patients with intolerance or lack of response to etidronate or etidronate/calcium,
  3. Paget's Disease,
  4. osteoporosis in patients who are 65 years of age and over.

DIN MFR Brand Name Effective Date
02310422 NOP NOVO-BENZYDAMINE 1.5MG/ML MWH 14/09/2009

Limited use benefit (prior approval required).

For:

  1. treatment of radiation mucositis and oral ulcerative complications of chemotherapy,
  2. use in immunocompromised patients who are at risk of mucosal breakdown.
DIN MFR Brand Name Effective Date
02293811 APX STAPO-LANSOPRAZOLE 15MG DR CAPSULE 14/07/2009
02293838 APX STAPO-LANSOPRAZOLE 30MG CAPSULE LA 14/07/2009
02318695 PDL STPANTOPRAZOLE 40MG DR TABLET 01/07/2009

Limited use benefit (prior approval required).

As part of multi-drug therapy (maximum 7-14 day coverage) for eradication of Helicobacter pylori in individuals with peptic ulcer disease (diagnosed by urea breath test, serology or endoscopically).

Coverage will also be provided if the following prerequisites are met:

  • patient has tried at least 30 days of Omeprazole (Losec®), AND
  • patient has tried at least 30 days of Rabeprazole sodium (Pariet®).

Total trial of 60 days will be confirmed against medication history

PLUS

  • for treatment of confirmed gastric and duodenal ulcers. Or
  • for mild to moderate gastroesophageal reflux disease (GERD) in patients who have failed on or not tolerated and 4-week trial of histamine-2 receptor antagonists. Or
  • for severe gastroesophageal reflux disease (GERD) and complications as first-line therapy for a maximum period of 3 months. Patients should be reassessed endoscopically or with step-down therapy using a histamine-2 receptor antagonist. Or
  • for treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers where the NSAID must be continued. Or
  • for prevention of NSAID-induced ulcers in patients who have a history of ulcer complications, are over the age of 65 years, have comorbid disease such as cardiovascular disease or coagulopathies or are on concomitant medications which increase risk of ulcers or bleeding. Or
  • Zollinger-Ellison Syndrome*. Or
  • Barrett's Esophagus*. Or
  • esophagitis associated with connective tissue disease. Or
  • other exceptional circumstances, evaluated on an individual basis.

*Diagnosis must be confirmed by a specialist qualified to diagnose and treat condition.

DIN MFR Brand Name Effective Date
02303442 ACP STACCEL PIOGLITAZONE 15MG TABLET 02/07/2009
02303450 ACP STACCEL PIOGLITAZONE 30MG TABLET 02/07/2009
02303469 ACP STACCEL PIOGLITAZONE 45MG TABLET 02/07/2009
02326477 MYL STMYLAN-PIOGLITAZONE 15MG TABLET 14/09/2009
02326485 MYL STMYLAN-PIOGLITAZONE 30MG TABLET 14/09/2009
02326493 MYL STMYLAN-PIOGLITAZONE 45MG TABLET 14/09/2009

Limited use benefit (prior approval required).

For the treatment of type 2 diabetic patients who are not adequately controlled by or are intolerant to metformin and sulfonylureas or for whom these products are contraindicated.

DIN MFR Brand Name Effective Date
02279215 APX APO-RALOXIFENE 60MG TABLET 26/05/2009
02312298 NOP NOVO-RALOXIFENE 60MG TABLET 14/09/2009

Limited use benefit (prior approval required).

For:

  1. secondary prevention of osteoporosis in women who experience failure on bisphosphonates,
  2. secondary prevention of osteoporosis in women who have a personal history or a first degree relative with a history of breast cancer.
DIN MFR Brand Name Effective Date
02298570 MYL MYLAN-TAMSULOSIN 0.4MG CAPSULE 25/05/2009

Limited use benefit (prior approval required).

For the treatment of Benign Prostatic Hyperplasia (BPH) in patients who do not tolerate or have not responded to other alpha-adrenergic blockers.

The following indications will be added to the NIHB Drug Benefit List:

DIN MFR Brand Name Effective Date
02247128 GIL VIREAD 245MG TABLET

Indication: For the treatment of chronic hepatitis B infection in patients with cirrhosis documented on radiologic or histologic ground and a HBV DNA concentration above 2000IU/mL.


Top of Page

Changes in Benefit Status

DIN MFR Brand Name Status Effective Date
02231462 SAC ALLEGRA (FEXOFENADINE) 60MG TABLET Removed from Formulary 01/01/2010

The Federal Pharmacy and Therapeutics Committee recently reviewed the evidence for the use of second generation (cetirizine, loratidine) and third generation (desloratidine, fexofenadine) antihistamines for their approved indication: seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Based on comparative trials, second and third generation antihistamines were found to be equally effective for all three indications therefore it was recommended that desloratadine not be added and fexofenadine be removed from the NIHB Drug Benefit List as of Jan 1, 2010. Clients who have received funding for fexofenadine in the 12 month period prior to this date will be grandfathered. Cetirizine and loratadine will remain as Open Benefit on the NIHB Drug Benefit List.

Effective October 1st, 2009, all glucometers will be removed from the NIHB formulary. This includes the following products:

DIN MFR Brand Name Effective Date
99401060 ROC ACCU-CHEK COMPACT 01/10/2009
09991039 ROC ACCU-CHEK COMPACT PLUS 01/10/2009
99401010 ROC ACCUSOFT 01/10/2009
99401046 ROC ACCUTREND GC 01/10/2009
97799934 BAY ASCENSIA BREEZE 01/10/2009
97799879 BAY ASCENSIA CONTOUR 01/10/2009
99401012 BAY ASCENSIA ELITE 01/10/2009
99401013 BAY ASCENSIA ELITE XL 01/10/2009
99401065 BTD BD LATITUDE 01/10/2009
99401011 BAY DEX 01/10/2009
99401061 THS FREESTYLE 01/10/2009
97799819 THS FREESTYLE MINI 01/10/2009
99401070 JAJ INDUO 01/10/2009
99401006 JAJ ONE TOUCH FASTTAKE 01/10/2009
99401058 JAJ ONE TOUCH ULTRA 01/10/2009
99401069 JAJ ONE TOUCH ULTRASMART 01/10/2009
99401001 AUC PRECISION QID 01/10/2009
99401003 AUC PRECISION QID COLOR W/O ELECTRODES BLUE 01/10/2009
99401004 AUC PRECISION QID COLOR W/O ELECTRODES RED 01/10/2009
99401005 AUC PRECISION QID PEN 01/10/2009
99401002 AUC PRECISION QID W/O ELECTRODES 01/10/2009
99401059 AUC PRECISION XTRA 01/10/2009
99401064 THM PRESTIGE SMART SYSTEM 01/10/2009

Note that there are no changes to the listing of test strips or other supplies for blood glucose monitoring.

Not Added to Formulary

The following drug products will not be added to the NIHB Drug Benefit List:
DIN MFR Brand Name
02284707 APX APO- LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02325942 APX APO- LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02325942 APX APO-LEVOFLOXACIN 750MG TABLET (LEVOFLOXACIN)
02315432 CBT CO- LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02315440 CBT CO- LEVOFLOXACIN 750MG TABLET (LEVOFLOXACIN)
02315424 CBT CO-LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02313979 GEN GEN-LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02313987 GEN GEN-LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02304767 MDX METOJECT 10MG/ML INJECTION (METHOTREXATE)
02248263 NOV NOVO- LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02285649 NOV NOVO- LEVOFLOXACIN 750MG TABLET (LEVOFLOXACIN)
02248262 NOV NOVO-LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02303671 NCC OMNARIS 50MCG/ACT NASAL SPRAY (CICLESONIDE)
02284677 PMS PMS-LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02284685 PMS PMS-LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02286947 PMS PMS-LEVOFLOXACIN 750MG TABLET (LEVOFLOXACIN)
02312441 BOE PRADAX 110MG CAPSULE (DABIGATRAN)
02312433 BOE PRADAX 75MG CAPSULE (DABIGATRAN)
02308215 WYE RELISTOR 20MG/ML INJECTION (METHYLNALTREXONE)
02213826 BAR REVIA 50MG TABLET (NALTREXONE)
02298635 SDZ SANDOZ- LEVOFLOXACIN 250MG TABLET (LEVOFLOXACIN)
02298643 SDZ SANDOZ- LEVOFLOXACIN 500MG TABLET (LEVOFLOXACIN)
02298651 SDZ SANDOZ- LEVOFLOXACIN 750MG TABLET (LEVOFLOXACIN)
02295636 PFI THELIN 10MG TABLET (SITAXSENTAN)
02307073 GSK VOLIBRIS 10MG TABLET (AMBRISENTAN)
02307065 GSK VOLIBRIS 5MG TABLET (AMBRISENTAN)
02268272 VAE XYREM 500MG/ML SOLUTION (SODIUM OXYBATE)

Drugs Discontinued by the Manufacturer

DIN MFR Brand Name
00402540 AZE BETALOC 100MG TABLET
00497827 AZE BETALOC 200MG TABLET
00402605 AZE BETALOC 50MG TABLET
02231676 PFR COVERA-HS 180MG TABLET
02231677 PFR COVERA-HS 240MG TABLET
02108186 NOV ESTRACOMB PATCH
00690228 VAL M.O.S 40MG TABLET
02224836 SAN RYTHMODAN LA 250MG TABLET

Name Changes

DIN Old Brand Name New Brand Name
MEAD JOHNSON NUTRITIONALS MEAD JOHNSON NUTRITION (CANADA) CO.
02242794 METFORMIN 500MG TABLET ZYM-METFORMIN 500MG TABLET
02242793 METFORMIN 850MG TABLET ZYM-METFORMIN 850MG TABLET

Manufacturer Changes

DIN Brand Name Old MFR New MFR
00031089 FERROUS FUMARATE 300MG TABLET PED JAP
02239139 LACTASE ENZYME 3000 ES TABLET SDR JAP
02239140 LACTASE ENZYME 4500 ES TABLET SDR JAP

Additions to the Short-Term Dispensing Policy Drug List

DIN Brand Name
02303442 ACCEL PIOGLITAZONE 15MG TABLET
02303450 ACCEL PIOGLITAZONE 30MG TABLET
02303469 ACCEL PIOGLITAZONE 45MG TABLET
02273381 APO-AMLODIPINE 10MG TABLET
02273373 APO-AMLODIPINE 5MG TABLET
02293838 APO-HYDRO 12.5MG TABLET
02293811 APO-LANSOPRAZOLE 15MG DR CAPSULE
02293838 APO-LANSOPRAZOLE 30MG DR CAPSULE
02324199 CALCIUM CARB/ETIDRONATE DISODI
02293269 CAMPRAL 333MG DR TABLET
02297493 CO AMLODIPINE 10MG TABLET
02297485 CO AMLODIPINE 5MG TABLET
02297302 CO PRAMIPEXOLE 0.25MG TABLET
02297310 CO PRAMIPEXOLE 0.5MG TABLET
02297337 CO PRAMIPEXOLE 1.5MG TABLET
02297329 CO PRAMIPEXOLE 1MG TABLET
02316846 CO-ROPINIROLE 0.25MG TABLET
02316854 CO-ROPINIROLE 1MG TABLET
02316862 CO-ROPINIROLE 2MG TABLET
02316870 CO-ROPINIROLE 5MG TABLET
02273225 ENABLEX 15MG SR TABLET
02273217 ENABLEX 7.5MG SR TABLET
80003010 EURO D 800IU CAP
02303825 EURO-DOCUSATE 100MG CAP
02285673 EURO-FOLIC 5MG TABLET
02272121 GEN-AMLODIPINE 10MG TABLET
02272113 GEN-AMLODIPINE 5MG TABLET
02329425 GEN-OMEPRAZOLE 10MG CAP LA
80008471 JAMP-MULTIVITAMIN A/D/ C DROPS
80009183 JAMP-SENNOSIDES 12MG TABLET
80009182 JAMP-SENNOSIDES 8.6MG TABLET
80009633 JAMP-VITAMIN B1 50MG TAB
02318709 MICARDIS PLUS 80MG/25MG TABLET
02317451 MINT-PRAVASTATIN 10MG TABLET
02317478 MINT-PRAVASTATIN 20MG TABLET
02317486 MINT-PRAVASTATIN 40MG TABLET
02299585 MYLAN-PANTOPRAZOLE 40MG TABLET
02326477 MYLAN-PIOGLITAZONE 15MG TABLET
02326485 MYLAN-PIOGLITAZONE 30MG TABLET
02326493 MYLAN-PIOGLITAZONE 45MG TABLET
02298570 MYLAN-TAMSULOSIN 0.4MG CAP
02250500 NOVO-AMLODIPINE 10MG TABLET
02250497 NOVO-AMLODIPINE 5MG TABLET
80000435 NOVO-FERROGLUC 300MG TABLET
02318695 PANTOPRAZOLE 40MG DR TABLET
02316544 PDL-GLYBURIDE 5MG TABLET
02299712 PHL-ALENDRONATE-FC 70MG TABLET
02326787 PHL-AMLODIPINE 10MG TABLET
02326779 PHL-AMLODIPINE 5MG TABLET
02284073 PMS-AMLODIPINE 10MG TABLET
02284065 PMS-AMLODIPINE 5MG TABLET
02326590 PMS-ROPINIROLE 0.25MG TABLET
02326512 PMS-ROPINIROLE 1MG TABLET
02326620 PMS-ROPINIROLE 2MG TABLET
02326639 PMS-ROPINIROLE 5MG TABLET
02321866 RAN-AMLODIPINE 10MG TABLET
02321858 RAN-AMLODIPINE 5MG TABLET
02314037 RAN-ROPINIROLE 0.25MG TABLET
02329158 RAN-SIMVASTATIN 10MG TABLET
02329166 RAN-SIMVASTATIN 20MG TABLET
02329174 RAN-SIMVASTATIN 40MG TABLET
02329131 RAN-SIMVASTATIN 5MG TABLET
02329182 RAN-SIMVASTATIN 80MG TABLET
02259613 RATIO-AMLODIPINE 10MG TABLET
02259605 RATIO-AMLODIPINE 5MG TABLET
02311194 RATIO-RAMIPRIL 15MG CAP
02284391 SANDOZ-AMLODIPINE 10MG TABLET
02284383 SANDOZ-AMLODIPINE 5MG TABLET
02323508 SIG-ENALAPRIL 16MG TABLET
02323478 SIG-ENALAPRIL 2MG TABLET
02323486 SIG-ENALAPRIL 4MG TABLET
02323494 SIG-ENALAPRIL 8MG TABLET
02305941 STALEVO 100MG/25MG/200MG TABLET
02305968 STALEVO 150MG/37.5MG/200MG TABLET
02305933 STALEVO 50MG/12.5MG/200MG TABLET
02267233 TECTA 40MG TABLET
00122645 VITAMIN B6 25MG TABLET
80008590 VITAMIN D 400IU CAPSULE
80008446 VITAMIN D 800 IU CAPSULE
00122858 VITAMIN E CAP 400IU NAT SOURCE
02321750 ZYM-ASA 80MG TABLET
02321769 ZYM-ASA EC 80MG TABLET

Removals from the Short-Term Dispensing Policy

DIN Brand Name
2170272 ANTI-DIARRHEAL 2MG TABLET
2212005 APO-LOPERAMIDE 2MG CAPLET
2192667 DIARR-EZE - LIQ ORL 0.2MG/ML
2229552 DIARR-EZE 2MG CAPLET
2256452 DIARRHEA RELIEF 2MG TABLET
2239535 DOM-LOPERAMIDE 2MG CAPLET
230197 GRAVOL LIQUID 15MG/5CC
2183862 IMODIUM 2MG CAPLET
2132591 NOVO-LOPERAMIDE 2 MG TABLET
2225182 PDL-LOPERAMIDE 2MG TABLET
757705 PMS-DIMENHYDRINATE SYRUP
2016095 PMS-LOPERAMIDE 0.2MG/ML SYRUP
2233998 RHOXAL-LOPERAMIDE 2MG CAP
2238211 RIVA-LOPERAMIDE 2MG TABLET
2257564 SANDOZ LOPERAMIDE 2MG TABLET
Date Modified: 2009-10-05

Top of Page
Important Notices